Modelling human disease with pluripotent stem cells

Current Gene Therapy

Volumn 13, Issue 2, 2013, Pages 99-110

  Siller, Richard ^a   Greenhough, Sebastian ^a   Park, In Hyun ^b   Sullivan, Gareth J ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Norwegian Center for Stem Cell Research   (Norway)

Author keywords

Disease modeling; Endodermal disorders; Human embryonic stem cells; Induced pluripotent stem cells; Mesodermal disorders; Neurodevelopmental disorders; Reprogramming

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL) ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL) PIPERIDINE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; CALPAIN; CISAPRIDE; CURCUMIN; FORSKOLIN; GAMMA SECRETASE INHIBITOR; GANCICLOVIR; GENTAMICIN; ISOPRENALINE; KINETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUMACAFTOR; MEVINOLIN; NICORANDIL; NIFEDIPINE; PINACIDIL; RANOLAZINE; ROSCOVITINE; SOMATOMEDIN C; SOTALOL; TOBRAMYCIN; UNCLASSIFIED DRUG; VALPROIC ACID; ZINC FINGER NUCLEASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL DIFFERENTIATION; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CYSTIC FIBROSIS; DIABETES MELLITUS; DOWN SYNDROME; DYSAUTONOMIA; EMBRYONIC STEM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; FANCONI ANEMIA; FRAGILE X SYNDROME; FRONTOTEMPORAL DEMENTIA; GAUCHER DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC MANIPULATION; GLYCOGEN STORAGE DISEASE TYPE 1; HEPATITIS C; HUMAN; HUNTINGTON CHOREA; INFECTION; LEOPARD SYNDROME; LESCH NYHAN SYNDROME; LONG QT SYNDROME; MACHADO JOSEPH DISEASE; NEOPLASM; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; RETT SYNDROME; ROTAVIRUS INFECTION; SPINAL MUSCULAR ATROPHY; WILSON DISEASE;

CELL DIFFERENTIATION; CELL LINEAGE; EMBRYONIC STEM CELLS; HUMANS; NEURODEGENERATIVE DISEASES; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELLS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84876720953     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523211313020004     Document Type: Article

References (112)

1. Briggs R and King TJ. Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs' Eggs. Proc Natl Acad Sci USA 1952; 38(5): 455-463.
2. Elsdale TR, Gurdon JB, and Fischberg M. A description of the technique for nuclear transplantation in Xenopus laevis. J Embryol Exp Morphol 1960; 8; 437-444.
3. Gurdon JB. Factors responsible for the abnormal development of embryos obtained by nuclear transplantation in Xenopus laevis. J Embryol Exp Morphol 1960; 8: 327-340.
4. Gurdon JB and Laskey RA. The transplantation of nuclei from single cultured cells into enucleate frogs' eggs. J Embryol Exp Morphol 1970; 24(2): 227-248.
5. Davis RL, Weintraub H and Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51(6): 987-1000.
6. Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385(6619): 810-813.
7. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
8. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
9. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2(12): 3081-3089.
10. Yu J, Vodyanik MA, Smuga-Otto K. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-1920.
11. Mochiduki Y and Okita K. Methods for iPS cell generation for basic research and clinical applications. Biotechnol J 2012; 7(6): 789-797.
12. Park IH, Arora N, Huo H. Disease-specific induced pluripotent stem cells. Cell 2008; 134(5): 877-886.
13. Wilmut I, Sullivan G and Chambers I. The evolving biology of cell reprogramming. Philos Trans R Soc Lond B Biol Sci 2011; 366(1575): 2183-2197.
14. Reeves RH, Irving NG, Moran TH. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 1995; 11(2): 177-184.
15. Hackam DG and Redelmeier DA. Translation of research evidence from animals to humans. JAMA 2006; 296(14): 1731-1732.
16. van der Worp HB, Howells DW, Sena ES. Can animal models of disease reliably inform human studies? PLoS Med 2010; 7(3): e1000245.
17. Kobayashi Y, Fukami T, Nakajima A, Watanabe A, Nakajima M, Yokoi T. Species Differences in Tissue Distribution and Enzyme Activities of Arylacetamide Deacetylase in Human, Rat, and Mouse. Drug Metab Dispos 2012; 40(4): 671-679.
18. Thomson JA, Itskovitz-Eldor J, Shapiro SS. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-1147.
19. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010; 6(5): 407-411.
20. Soldner F, Laganière J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011; 146(2): 318-331.
21. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29(8): 731-734.
22. Carroll D. Zinc-finger nucleases: a panoramic view. Curr Gene Ther 2011; 11(1): 2-10.
23. Silva G, Poirot L, Galetto R, et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 2011; 11(1): 11-27.
24. Ben-Yosef D, Malcov M and Eiges R. PGD-derived human embryonic stem cell lines as a powerful tool for the study of human genetic disorders. Mol Cell Endocrinol 2008; 282(1-2): 153-158.
25. Bradley CK, Scott HA, Chami O, et al. Derivation of Huntington's disease-affected human embryonic stem cell lines. Stem Cells Dev 2011; 20(3): 495-502.
26. Pickering SJ, Minger SL, Patel M, et al. Generation of a human embryonic stem cell line encoding the cystic fibrosis mutation deltaF508, using preimplantation genetic diagnosis. Reprod Biomed Online 2005; 10(3): 390-397.
27. Tropel P, Tournois J, Côme J, et al. High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis. In vitro Cell Dev Biol Anim 2010; 46(3/4): 376-385.
28. Mateizel I, De Temmerman N, Ullmann U, et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 2006; 21(2): 503-511.
29. Mateizel I, Spits C, De Rycke M, Liebaers I, Sermon K. Derivation, culture, and characterization of VUB hESC lines. In vitro Cell Dev Biol Anim 2010; 46(3/4): 300-308.
30. Eiges R, Urbach A, Malcov M, et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007; 1(5): 568-577.
31. Lannon BM, et al. Derivation of the first human embryonic stem cell line with Charcot Marie Tooth disease. Fertil Steril 2009; 92(3): 171-172.
32. Ben-Nun IF, Montague SC, Houck ML, et al. Induced pluripotent stem cells from highly endangered species. Nat Methods 2011; 8(10): 829-831.
33. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457(7227): 277-280.
34. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009; 461(7262): 402-406.
35. Slaugenhaupt SA, Mull J, Leyne M, et al. Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 2004; 13(4): 429-436.
36. Lee G and Studer L. Modelling familial dysautonomia in human induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci 2011; 366(1575): 2286-2296.
37. Kim KY, Jung YW, Sullivan GJ, Chung L, Park IH. Cellular reprogramming: a novel tool for investigating autism spectrum disorders. Trends Mol Med 2012; 18(8): 463-471.
38. Pasinelli P and Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7(9): 710-723.
39. Bilican B, Serio A, Barmada SJ, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci USA 2012; 109(15): 5803-5808.
40. Hoekstra M, Mummery CL, Wilde AA, Bezzina CR, Verkerk AO. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol 2012; 3: 346.
41. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471(7337): 225-229.
42. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007; 8(10): 735-748.
43. Raya A, Rodríguez-Pizà I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460(7251): 53-59.
44. Müller LU, Schlaeger TM, DeVine AL, Williams DA. Induced pluripotent stem cells as a tool for gaining new insights into Fanconi anemia. Cell Cycle 2012; 11(16): 2985-2990.
45. Müller LU, Milsom MD, Harris CE, et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012; 119(23): 5449-5457.
46. Panicker LM, Miller D, Park TS, et al., Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci USA 2012; 109(44): 18054-18059.
47. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998; 12(4): 240-244.
48. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993; 52(1): 85-88.
49. Chou ST, Byrska-Bishop M, Tober JM, et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109(43): 17573-17578.
50. Maclean GA, Menne TF, Guo G, et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA 2012; 109(43): 17567-17572.
51. Li LB, Chang KH, Wang PR, Hirata RK, Papayannopoulou T, Russell DW. Trisomy Correction in Down Syndrome Induced Pluripotent Stem Cells. Cell Stem Cell 2012; 11(5): 615-619.
52. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120(9): 3127-3136.
53. Ghodsizadeh A, Taei A, Totonchi M, et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev 2010; 6(4): 622-632.
54. Cayo MA, Cai J, DeLaForest A, et al. JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 2012; 56(6): 2163-2171.
55. Zhang S, Chen S, Li W, et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet 2011; 20(16): 3176-3187.
56. Yi F, Qu J, Li M, et al. Establishment of hepatic and neural differentiation platforms of Wilson's disease specific induced pluripotent stem cells. Protein Cell 2012; 3(11): 855-863.
57. Wong AP, Bear CE, Chin S, et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol 2012; 30(9): 876-882.
58. Mou H, Zhao R, Sherwood R, et al. Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs. Cell Stem Cell 2012; 10(4): 385-397.
59. Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci USA 2009; 106(37): 15768-15773.
60. Ohmine S, Squillace KA, Hartjes KA, et al. Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging (Albany NY) 2012; 4(1): 60-73.
61. Maehr R. iPS cells in type 1 diabetes research and treatment. Clin Pharmacol Ther 2011; 89(5): 750-753.
62. Kao DI and Chen S. Pluripotent stem cell-derived pancreatic betacells: potential for regenerative medicine in diabetes. Regen Med 2012; 7(4): 583-593.
63. Yoshizaki S, Nishi M, Kondo A, Kojima Y, Yamamoto N, Ryo A. Vaccination with human induced pluripotent stem cells creates an antigen-specific immune response against HIV-1 gp160. Front Microbiol 2011; 2: 27.
64. Ni Z, Knorr DA, Clouser CL, et al. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J Virol 2011; 85(1): 43-50.
65. Jerebtsova M, Kumari N, Xu M, et al. HIV-1 Resistant CDK2- Knockdown Macrophage-Like Cells Generated from 293T Cell-Derived Human Induced Pluripotent Stem Cells. Biology (Basel) 2012; 1(2): 175-195.
66. Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109(7): 2544-25848.
67. Wu X, Robotham JM, Lee E, et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012; 8(4): e1002617.
68. Yoshida T, Takayama K, Kondoh M, et al. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. Biochem Biophys Res Commun 2011; 416(1-2): 119-124.
69. Spence JR, Mayhew CN, Rankin SA, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 2011; 470(7332): 105-109.
70. Finkbeiner SR, Zeng XL, Utama B, Atmar RL, Shroyer NF, Estes MK. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. MBio 2012; 3(4): e00159-12.
71. Klotz C, Aebischer T and Seeber F. Stem cell-derived cell cultures and organoids for protozoan parasite propagation and studying host-parasite interaction. Int J Med Microbiol 2012; 302(4-5): 203-209.
72. Howell JC and Wells JM. Generating intestinal tissue from stem cells: potential for research and therapy. Regen Med 2011; 6(6): 743-755.
73. Wang A and Sander M. Generating cells of the gastrointestinal system: current approaches and applications for the differentiation of human pluripotent stem cells. J Mol Med (Berl) 2012; 90(7): 763-771.
74. Blelloch RH, Hochedlinger K, Yamada Y, et al. Nuclear cloning of embryonal carcinoma cells. Proc Natl Acad Sci USA 2004; 101(39): 13985-132990.
75. Ghosh Z, Huang M, Hu S, Wilson KD, Dey D, Wu JC. Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res 2011; 71(14): 5030-5039.
76. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471(7336): 63-67.
77. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471(7336): 58-62.
78. Bernhardt M, Galach M, Novak D, Utikal J, et al. Mediators of induced pluripotency and their role in cancer cells - current scientific knowledge and future perspectives. Biotechnol J 2012; 7(6): 810-821.
79. Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgenefree induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011; 117(14): e109-e119.
80. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14(10): 2115-2124.
81. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122(Pt 19): 3502-3510.
82. Mahalingam D, Kong CM, Lai J, Tay LL, Yang H, Wang X. Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells. Sci Rep 2012; 2: 592.
83. Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2010; 107(1): 40-45.
84. Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011; 8(4): 376-388.
85. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2012 [Epub ahead of print].
86. Tomoda K, Takahashi K, Leung K, et al. Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell 2012; 11(1): 91-99.
87. Anguera MC, Sadreyev R, Zhang Z, et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell 2012; 11(1): 75-90.
88. Patterson M, Chan DN, Ha I, et al. Defining the nature of human pluripotent stem cell progeny. Cell Res 2012; 22(1): 178-193.
89. Thery M. Micropatterning as a tool to decipher cell morphogenesis and functions. J Cell Sci 2010; 123(Pt 24): 4201-4213.
90. Müller FJ, Schuldt BM, Williams R, et al. A bioinformatic assay for pluripotency in human cells. Nat Methods 2011; 8(4): 315-317.
91. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012; 482(7384): 216-220.
92. Yagi T, Ito D, Okada Y, et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet 2011; 20(23): 4530-4539.
93. Yahata N, Asai M, Kitaoka S, et al. Anti-Abeta drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One 2011; 6(9): e25788.
94. Camnasio S, Delli Carri A, Lombardo A, et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012; 46(1): 41-51.
95. An MC, Zhang N, Scott G, et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012; 11(2): 253-263.
96. Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, et al. Disease-specific phenotypes in dopamine neurons from human iPSbased models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012; 4(5): 380-395.
97. Imaizumi Y, Okada Y, Akamatsu W, et al. Mitochondrial dysfunction associated with increased oxidative stress and alphasynuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 2012; 5(1): 35.
98. Hotta A, Cheung AY, Farra N, et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 2009; 6(5): 370-376.
99. Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143(4): 527-539.
100. Amenduni M, De Filippis R, Cheung AY, et al. iPS cells to model CDKL5-related disorders. Eur J Hum Genet 2011; 19(12): 1246-1255.
101. Paşca SP, Portmann T, Voineagu I, et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011; 17(12): 1657-1662.
102. Koch P, Breuer P, Peitz M, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011; 480(7378): 543-546.
103. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363(15): 1397-1409.
104. Lahti AL, Kujala VJ, Chapman H, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012; 5(2): 220-230.
105. Novak A, Barad L, Zeevi-Levin N, et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation. J Cell Mol Med 2012; 16(3): 468-482.
106. Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012; 4(130): 130-147.
107. Jiang Y, Cowley SA, Siler U, et al. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells 2012; 30(4): 599-611.
108. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465(7299): 808-812.
109. Fujikura J, Nakao K, Sone M, et al. Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia 2012; 55(6): 1689-1698.
110. Zhang J, Lian Q, Zhu G, et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011; 8(1): 31-45.
111. Liu GH, Barkho BZ, Ruiz S, et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011; 472(7342): 221-225
112. Bedel A, Taillepierre M, Guyonnet-Duperat V, et al. Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors. Am J Hum Genet 2012; 91(1): 109-121